Skip to main navigation Skip to search Skip to main content

Safety and Clinical Study of Calcium Pantetheine-S-Sulfonate in Patients with Hyperpigmentation

Research output: Contribution to journalArticlepeer-review

Abstract

Calcium Pantetheine-S-Sulfonate (PaSSOsCa) is one of the pantothenic acid derivatives. We examined PaSSOaCa inhibition capacity of melanin formation in vitro. For the safety evaluation, we tested PaSSOsCa cream to the fifty one patients with skin diseases by closed patch method. And clinical evaluation of PaSSOsCa was performed in the fifty patients with hyperpigmentation by half side method. Results were as follows; 1. We showed PaSSOsCa inhibition capacity of melanin formation in vitro. 2. PaSSOsCa cream was shown to be safety to the human skin. 3. 10% PaSSOsCa cream lightened the skin hyperpigmentation more than placebo cream.

Original languageEnglish
Pages (from-to)162-174
Number of pages13
Journal[Hifu] Skin research
Volume26
Issue number1
DOIs
Publication statusPublished - 1984
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety and Clinical Study of Calcium Pantetheine-S-Sulfonate in Patients with Hyperpigmentation'. Together they form a unique fingerprint.

Cite this